Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 06 Feb 2019

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Letrozole (Primary) ; Anastrozole
Indications Early breast cancer
Focus Registrational; Therapeutic Use
Acronyms FACE
Sponsors Novartis

Most Recent Events

23 Jan 2017 Final results published in the Journal of Clinical Oncology.
12 Dec 2015 Results presented at the 38th Annual San Antonio Breast Cancer Symposium
12 Dec 2015 Primary endpoint "Disease-free survival rate" has not been met, as per the results presented at the 38th Annual San Antonio Breast Cancer Symposium.

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight